Startseite>>Signaling Pathways>> GPCR/G protein>> CXCR>>CXCR2-IN-2

CXCR2-IN-2

Katalog-Nr.GC62475

CXCR2-IN-2 ist ein selektiver, ins Gehirn eindringender und oral bioverfÜgbarer CXCR2-Antagonist (IC50 = 5,2 nM/1 nM im β-Arrestin-Assay bzw. CXCR2-Tango-Assay).

Products are for research use only. Not for human use. We do not sell to patients.

CXCR2-IN-2 Chemische Struktur

Cas No.: 1838123-21-9

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
396,00 $
Auf Lager
5 mg
360,00 $
Auf Lager
10 mg
612,00 $
Auf Lager
25 mg
1.215,00 $
Auf Lager
50 mg
1.980,00 $
Auf Lager
100 mg
3.060,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

CXCR2-IN-2 is a selective, brain penetrant, and orally bioavailable CXCR2 antagonist (IC50=5.2 nM/1 nM in β-arrestin assay/CXCR2 Tango assay, respectively). CXCR2-IN-2 displays ~730-fold selectivity over CXCR1 and >1900-fold selectivity over all other chemokine receptors. CXCR2-IN-2 inhibits human whole blood Gro-α induced CD11b expression with an IC50 of 0.04 μM[1].

CXCR2-IN-2 (compound 68) (1-10 mg/kg; p.o.; twice daily for 3 days) dose-dependently reduces neutrophil infiltration in vivo in rat and mouse air pouch models[1].

[1]. Lu H, et al. Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists. J Med Chem. 2018;61(6):2518-2532.

Bewertungen

Review for CXCR2-IN-2

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CXCR2-IN-2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.